Evidence map›Paper›PMID 37907987›Full record

ArticleJournal of nanobiotechnology2023

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.

Lijuan Chong, Yao-Wen Jiang, Dongxu Wang, Pengzhao Chang, Kai Xu, Jingjing Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Microglial polarization in retinal neovascularization: Friend or foe?Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Sericin-coated MnOScientific reports · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lijuan Chong *School of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
Yao-Wen Jiang *School of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
Dongxu WangSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
Pengzhao ChangSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
Kai XuSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. xkpaper@163.com.
Jingjing LiSchool of Medical Imaging, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China. qingchao0124@163.com.
Xuzhou Medical College · CN

Funding

Initializing Fund of Xuzhou Medical University RC20552301National Natural Science Foundation of China 8217071424Natural Science Foundation of Jiangsu Province BK20221391Six one project of Jiangsu Province LGY2018083
6 · The paper itself

Abstract

Anti-tumor M1-like and pro-tumor M2-like tumor-associated macrophages (TAMs) coexist in tumor microenvironments (TME). The adverse effects of these M1/M2 subsets on tumors directly affect the current strategies to improve anti-tumor immune response. Therefore, it has attracted great attention to change the tumor immunosuppressive microenvironment by reprogramming TAMs. In this paper, we constructed biomimetic nanoparticles (HMMDN-Met@PM) targeting M2-like TAMs for macrophage re-polarization. In detail, the core of the biomimetic nanoparticles is metformin-loaded hollow mesoporous manganese dioxide nanoparticles (HMMDN-Met). Benefited from the hollow and porous structure of HMMDN, metformin, the regulator of M1/M2 adopted in this work, can be easily and widely loaded into HMMDN. Moreover, macrophage membranes were utilized for HMMDN-Met coating (HMMDN-Met@MM) to prevent the premature drug leakage and provide specific molecular recognition/TME targeting. In addition, M2 macrophage targeting peptide (M2pep) was modified on the surface of macrophage membrane to specifically deliver the drug to M2-like TAMs to promote the polarization of M2 to M1 macrophages. Through in vitro and in vivo studies, we found that the expression of surface markers and inflammatory factors CD206, Arg-1 and IL-10 of type M2 macrophages decreased, while the surface markers of type M1 macrophages and the expression of inflammatory factors CD80, TNF-α and iNOS increased, indicating the successful re-polarization of M2 macrophages and finally realizing the inhibition of tumor growth. At the same time, under the acidic and GSH conditions of tumor, HMMDN was decomposed into Mn

Indexed as

MetforminNanoparticlesNeoplasmsBiomimeticsHumansImmunotherapyMagnetic Resonance ImagingTumor-Associated MacrophagesTumor MicroenvironmentMetforminBiomimetic nanoparticlesImmumotherapyMagnetic resonance imagingRe-polarizationTumor-associated macrophages

Identifiers

PMID37907987
PMCPMC10617215
OpenAlexW4388088683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.